[go: up one dir, main page]

WO2024249839A8 - Methods of treating cancer in subjects with prior immune checkpoint inhibitor exposure - Google Patents

Methods of treating cancer in subjects with prior immune checkpoint inhibitor exposure

Info

Publication number
WO2024249839A8
WO2024249839A8 PCT/US2024/031972 US2024031972W WO2024249839A8 WO 2024249839 A8 WO2024249839 A8 WO 2024249839A8 US 2024031972 W US2024031972 W US 2024031972W WO 2024249839 A8 WO2024249839 A8 WO 2024249839A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
subjects
treating cancer
immune checkpoint
checkpoint inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/031972
Other languages
French (fr)
Other versions
WO2024249839A1 (en
Inventor
Mariano SEVERGNINI
Gaurav CHOUDHARY
Maureen E. LANE
Samantha M. CARLISLE
David C. Nickle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of WO2024249839A1 publication Critical patent/WO2024249839A1/en
Publication of WO2024249839A8 publication Critical patent/WO2024249839A8/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates to methods of treating certain diseases and disorders (e.g., IRAK4-associated diseases and disorders).
PCT/US2024/031972 2023-06-01 2024-05-31 Methods of treating cancer in subjects with prior immune checkpoint inhibitor exposure Pending WO2024249839A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363470361P 2023-06-01 2023-06-01
US63/470,361 2023-06-01

Publications (2)

Publication Number Publication Date
WO2024249839A1 WO2024249839A1 (en) 2024-12-05
WO2024249839A8 true WO2024249839A8 (en) 2025-10-09

Family

ID=93658456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/031972 Pending WO2024249839A1 (en) 2023-06-01 2024-05-31 Methods of treating cancer in subjects with prior immune checkpoint inhibitor exposure

Country Status (1)

Country Link
WO (1) WO2024249839A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ722019A (en) 2014-01-13 2022-07-01 Aurigene Discovery Tech Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors

Also Published As

Publication number Publication date
WO2024249839A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
WO2020205473A8 (en) Compositions and methods for the treatment of kras associated diseases or disorders
CA3183032A1 (en) Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
NO20071426L (en) Cancer combination therapy including AZD2171 and Imatinib
DE60228235D1 (en) ANIMAL NUTRITIONAL COMPOSITION FOR IMPROVING THE SKIN
WO2022216379A8 (en) Combination therapies for the treatment of cancer
WO2024249839A8 (en) Methods of treating cancer in subjects with prior immune checkpoint inhibitor exposure
WO2004031105A3 (en) Use of a33 antigens and jam-it
WO2018208793A8 (en) S-nitrosoglutathione (gsno) and gsno reductase inhibitors for use in therapy
WO2008118733A3 (en) Methods of treating cancer by administering human il-18 combinations
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
MX2024001269A (en) Rock2 inhibitors and uses thereof.
DE602007005041D1 (en) Process for the treatment of inflammatory diseases with passion fruit extracts
WO2019204332A3 (en) Pak4 inhibitors and methods of use
EA202192964A1 (en) COMBINATION THERAPY
WO2021011844A3 (en) Combination cancer therapy agents and methods
WO2004016151A3 (en) Pthrp-derived modulators of smooth muscle proliferation
DE69123984D1 (en) USE OF ANTIBODIES AGAINST TNF OR THE DERIVED FRAGMENTS AND XANTHINE DERIVATIVES IN COMBINATION THERAPY AND COMPOSITIONS THEREOF
MX2025004473A (en) Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
MX2022003944A (en) Biomarker panels for guiding dysregulated host response therapy.
WO2019241742A8 (en) Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
WO2020176461A3 (en) Methods and compositions for treating neuroendocrine prostate cancer
WO2024108114A3 (en) Methods of selecting cancer patients amendable to treatment with immune checkpoint inhibitor
DE502005010502D1 (en) A pharmaceutical composition, use of said pharmaceutical composition for the manufacture of a medicament and / or a nutritional supplement for the treatment of obesity and / or overweight-related symptoms in humans or mammals, and methods for the preparation of said pharmaceutical composition
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
WO2023019095A3 (en) Momelotinib combination therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24816557

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2024281302

Country of ref document: AU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025026165

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2024281302

Country of ref document: AU

Date of ref document: 20240531

Kind code of ref document: A